IGF1R antibody (Chain alpha)

Catalog No. ABIN181732

This Mouse Monoclonal antibody specifically detects IGF1R in WB, FACS and IHC (p). It exhibits reactivity toward Human. It has been mentioned in 3+ publications

Quick Overview for IGF1R antibody (Chain alpha) (ABIN181732)

Target: IGF1R (Insulin-Like Growth Factor 1 Receptor (IGF1R))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This IGF1R antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: 1H7

Product Details anti-IGF1R Antibody

Binding Specificity: Chain alpha

Specificity: This antibody recognises CD221. The ligands for CD221 include IGF-I and IGF-II, which bind to CD221 and activate tyrosine kinase activity, resulting in phosphorylation of several intracellular signalling proteins. Clone 1H7 is reported to partically block binding of IGF-I and IGF-II to CD221. We recommend the use of BM2226LE for this purpose.

Purification: Affinity Chromatography on Protein G

Immunogen: Spleen cells from immunised BALB/c mice were fused with cells of the SP2/0 myeloma cell line.

Isotype: IgG1

Application Details

Application Notes: Western Blot. Flow Cytometry: Use 10 μL of 1/10 diluted antibody to label 10^6 cells in 100 μL. Immunohistochemistry on Paraffin Sections (1/10-1/40): Requires protein digestionpre-treatment. Recommended Positive Control: Pancreas, placenta.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: PBS, pH 7.4 containing 0.09 % Sodium Azide as preservative.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

References for anti-IGF1R antibody (ABIN181732)

Beuschlein, Jakoby, Mentz, Zambetti, Jung, Reincke, Süss, Hantel: "IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma." in: Molecular and cellular endocrinology, Vol. 428, pp. 82-8, (2016) (PubMed).

Hantel, Lewrick, Reincke, Süss, Beuschlein: "Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma." in: The Journal of endocrinology, Vol. 213, Issue 2, pp. 155-61, (2012) (PubMed).

Hantel, Lewrick, Schneider, Zwermann, Perren, Reincke, Süss, Beuschlein: "Anti insulin-like growth factor I receptor immunoliposomes: a single formulation combining two anticancer treatments with enhanced therapeutic efficiency." in: The Journal of clinical endocrinology and metabolism, Vol. 95, Issue 2, pp. 943-52, (2010) (PubMed).

Target Details for IGF1R

Target: IGF1R (Insulin-Like Growth Factor 1 Receptor (IGF1R))

Alternative Name: CD221 / IGF1R

Background: CD221 is a 155kD receptor tyrosine kinase, also known as Insulin-like growth factor I receptor (IGF-I Receptor). CD221 is composed of two extracellular alpha-subunits and two transmembrane beta-subunits. CD221 is expressed in a range of tissues, including kidney, liver, placenta, mammary gland, brain, ovary and skin.Synonyms: IGF-I receptor, IGF1 Receptor, Insulin-like growth factor 1 receptor

Gene ID: 3480

NCBI Accession: NP_000866

UniProt: P08069

Pathways: RTK Signaling, Regulation of Hormone Metabolic Process, Regulation of Hormone Biosynthetic Process, Autophagy